Clinical Trials | A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (MK-2870-020/GOG-3101/ENGOT-cx20)
The University of Virginia seeks adult women ages 18 years and older with recurrent or metastatic cervical cancer. You may be eligible for this study if: • You have squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix • You have had one or more prior lines of systemic platinum chemotherapy and prior immunotherapy You will be randomized (assigned by chance) to one of two treatment arms, • Arm 1: MK2870 4mg/kg administered intravenously • Arm2: Treatment of Physician’s choice consisting of one of the following: Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan. This study involves blood draw, imaging of the chest, abdomen and pelvis, electrocardiogram (ECG), Echocardiogram (ECHO) and archival tissue collection. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.